SCHEMBL16196902

SCHEMBL16196902

CCn1ncn(-c2ccc(Br)cc2)c1=O

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 10/20 0.48
PPARA Q07869 10/20 0.48
PPARG P37231 7/20 0.48
HSD17B3 P37058 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
ROCK2 O75116 2/20 0.39
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
HTT P42858 1/20 0.37
HSP90AA1 P07900 1/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20639871 0.91 MAPT (0.49) PPARDPPARAPPARGHSD17B3SMN1; SMN2
SCHEMBL26499325 0.87 PPARD (0.46) PPARDPPARAPPARGHSD17B3SMN1; SMN2
SCHEMBL25160199 0.85 PPARD (0.48) PPARDPPARAPPARGHSD17B3SMN1; SMN2
SCHEMBL20644446 0.83 PPARD (0.51) PPARDPPARAPPARGHSD17B3ROCK2
SCHEMBL22349793 0.83 PPARD (0.48) PPARDPPARAPPARGHSD17B3SMN1; SMN2
SCHEMBL26499330 0.83 HSD17B3 (0.39) PPARDPPARAPPARGHSD17B3SMN1; SMN2
SCHEMBL22349797 0.83 PPARD (0.48) PPARDPPARAPPARGHSD17B3SMN1; SMN2
SCHEMBL30203145 0.83 PPARD (0.51) PPARDPPARAPPARGHSD17B3SMN1; SMN2
SCHEMBL22349850 0.83 ALDH1A1 (0.47) PPARDPPARAPPARGSMN1; SMN2RAB9A
SCHEMBL16196818 0.83 PPARD (0.48) PPARDPPARAPPARGHSD17B3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321082-A1 USE OF TRIAZOLE ANALOGUES FOR INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS BOE TECHNOLOGY GROUP CO., LTD. (CN) 2023-10-12 US disclosed
US-20230321082-A1 USE OF TRIAZOLE ANALOGUES FOR INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS BOE TECHNOLOGY GROUP CO., LTD. (CN) 2023-10-12 US disclosed
US-9663495-B2 Triazolone derivatives or salts thereof and pharmaceutical composition comprising the same YUHAN CORPORATION (KR) 2017-05-30 US disclosed
US-20160068515-A1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME YUHAN CORPORATION (KR) 2016-03-10 US disclosed
EP-2989093-A1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Yuhan Corporation (KR) 2016-03-02 EP disclosed
WO-2014175621-A1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME YUHAN CORPORATION (KR) 2014-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321082-A1 USE OF TRIAZOLE ANALOGUES FOR INHIBITION OF A TRIPARTITE VOR PROTEIN COMPLEX IN MULTICELLULAR ORGANISMS RABL3, VAPA, VAPB PPARD 1920/4885PPARA 2605/4885PPARG 1912/4885
US-20160068515-A1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME GPR119, GPR88, GCGR PPARD 133/4885PPARA 179/4885PPARG 56/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.